MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Impact of datscan on clinical decision making: diagnosis and management of clinically uncertain Parkinsonian syndromes

J.R. Isaacson, N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

Meeting: 2016 International Congress

Abstract Number: 1330

Keywords: Parkinsonism

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Neuroimaging and neurophysiology

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To assess changes in clinical diagnosis and/or treatment of 200 consecutive patients with clinically uncertain Parkinsonian syndromes who underwent DaTscan imaging with ioflupane for striatal dopamine transporter degeneration.

Background: Clinically, the differentiation of parkinsonism can be challenging. It is not uncommon for patients to be initially treated, but later to have diagnosis revised and treatment changed. Striatal dopamine transporter is a marker of presynaptic dopaminergic neuroterminals. Datscan imaging can identify loss of striatal dopamine transporters, indicative of dopaminergic degeneration. Striatal dopamine transporter imaging can help distinguish between Parkinsonian disorders with (PD, SND, PSP, etc) and without (drug-induced, ET, vascular, etc) dopaminergic degeneration.

Methods: Retrospective ongoing analysis of 100 consecutive patients whose clinical diagnosis was unclear and in whom a movement disorder specialist ordered DATscan imaging to clarify diagnosis by determining whether dopaminergic degeneration was present. All patients had assessment of % likely abnormal scan prior to imaging based on clinical examination and prior treatment response. After DaTscan imaging, changes to clinical diagnosis and treatment were assessed.

Results: 51% of patients had an uncertain provisional diagnosis confirmed, 6% of patients had clarification between two provisional diagnoses, and 42% of imaged patients had a provional diagnosis changed. We identified several clinical scenarios where Datscan imaging seem most useful: drug-induced; prominent action tremor; lower extremity predominant; early subtle signs with nonmotor symptoms; and clinically stable and/or without fluctuations after 5 years. Changes in treatment followed clarification of clinical diagnosis and whether striataonigral dopaminergic degeneration was identified on Datscan. Overall, 21% had a medication stopped, 34% had a medication begun, and 26% had a medication changed.

Conclusions: In several clinical scenarios in which diagnosis of Parkinsonian syndromes is unclear, visualization of striatal dopamine transporters using DaTscan can differentiate between disorders with and without nigrostriatal dopaminergic degeneration, clarifying diagnosis and impacting treatment.

An interim analysis of the initial 100 patients was presented at MDS in San Diego 2015.

To cite this abstract in AMA style:

J.R. Isaacson, N. Chhabria, S.H. Isaacson. Impact of datscan on clinical decision making: diagnosis and management of clinically uncertain Parkinsonian syndromes [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/impact-of-datscan-on-clinical-decision-making-diagnosis-and-management-of-clinically-uncertain-parkinsonian-syndromes/. Accessed June 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/impact-of-datscan-on-clinical-decision-making-diagnosis-and-management-of-clinically-uncertain-parkinsonian-syndromes/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #23660 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley